Abstract: A method is provided for preparing a water-insoluble lignosulfonate polymer from a first solution containing lignosulfonate precursors, which involves a) separating the lignosulfonate precursors from the first solution and providing a second solution with at least 5 wt % of lignosulfonate precursors obtained from the first solution, wherein the separating comprises filtering out components with a predefined particle diameter and separating low-molecular weight components including salts and low-molecular organic compounds, b) adding a radical-forming enzyme and gas to the second solution, wherein the gas comprises oxygen, and c) polymerizing the lignosulfonate precursors of the resultant solution of b). Other related aspects are described and claimed.

Abstract: The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Abstract: A method is provided for preparing a water-insoluble lignosulfonate polymer from a first solution containing lignosulfonate precursors, which involves a) separating the lignosulfonate precursors from the first solution and providing a second solution with at least 5 wt % of lignosulfonate precursors obtained from the first solution, wherein the separating comprises filtering out components with a predefined particle diameter and separating low-molecular weight components including salts and low-molecular organic compounds, b) adding a radical-forming enzyme and gas to the second solution, wherein the gas comprises oxygen, and c) polymerizing the lignosulfonate precursors of the resultant solution of b). Other related aspects are described and claimed.

Abstract: Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

Abstract: Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone.

Abstract: Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone.

Abstract: Disclosed are pharmaceutical compositions comprising a drug with a laccase-reactive functional group and a laccase (EC.10.3.2) and methods for manufacturing such compositions.

Abstract: Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.